Eran Ovadya is a seasoned financial executive and educator with extensive experience in the biotechnology and financial services sectors. Currently serving as Chief Financial Officer at NurExone Biologic since April 2021 and as an Independent Director at Neural Therapeutics since December 2024, Eran Ovadya has previously held significant roles at multiple organizations, including Chief Financial Officer at Silexion Therapeutics Corp and Procore Bio-Med Ltd, as well as Senior Finance Director at Gamida Cell Ltd. An entrepreneur, Eran Ovadya also founded Selo Financial Services, providing outsourced CFO services, and was the founder and CEO of BizValue, a SaaS company focused on enterprise valuations. Additionally, Eran Ovadya has been a lecturer at Bar-Ilan University since 2017, teaching business valuation techniques. Educational qualifications include a Master's Degree in Analyst & Business Valuation Certification from Bar-Ilan University, an MBA in Business/Managerial Economics from The Open University of Israel, and a Bachelor's degree in Accounting and Economics from the same institution.
This person is not in any teams
This person is not in any offices
NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.